Cargando...
Perspectives on metals-based radioimmunotherapy (RIT): moving forward
Radioimmunotherapy (RIT) is FDA-approved for the clinical management of liquid malignancies, however, its use for solid malignancies remains a challenge. The putative benefit of RIT lies in selective targeting of antigens expressed on the tumor surface using monoclonal antibodies, to systemically de...
Gardado en:
| Publicado en: | Theranostics |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Ivyspring International Publisher
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8120204/ https://ncbi.nlm.nih.gov/pubmed/33995659 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.57177 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|